We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Study Identifies Molecular Signatures in Arthritis Patients for Incorporation In Diagnostic Tests

By LabMedica International staff writers
Posted on 20 May 2022
Print article
Image: Molecular profiling of diseased joint tissue can predict response to arthritis treatment (Photo courtesy of QMUL)
Image: Molecular profiling of diseased joint tissue can predict response to arthritis treatment (Photo courtesy of QMUL)

Much progress has been made over the past decades in treating rheumatoid arthritis (RA), although a significant number of patients (approximately 40%) do not respond to specific drug therapies, and 5-20% of people with the disease are resistant to all current forms of medication. New research has shown that molecular profiling of the diseased joint tissue can significantly impact whether specific drug treatments will work to treat RA patients. The incorporation of these molecular signatures in future diagnostic tests will be a necessary step to translate these findings into routine clinical care.

Researchers at Queen Mary University of London (QMUL, London, UK) have also identified specific genes associated with resistance to most available drugs therapies, commonly referred to as refractory disease, which could provide the key to developing new, successful drugs to help these people. The researchers carried out a biopsy-based clinical trial, involving 164 arthritis patients, in which their responses to either rituximab or tocilizumab – two drugs commonly used to treat RA – were tested. The results of the original trial demonstrated that in those patients with a low synovial B-cell molecular signature only 12% responded to a medication that targets B cells (rituximab), whereas 50% responded to an alternative medication (tocilizumab). When patients had high levels of this genetic signature, the two drugs were similarly effective.

As part of the first-of-its-kind study, the team also looked at the cases where patients did not respond to treatment via any of the drugs and found that there were 1,277 genes that were unique to them specifically. Building on this, the researchers applied a data analyses technique called machine learning models to develop computer algorithms which could predict drug response in individual patients. The machine learning algorithms, which included gene profiling from biopsies, performed considerably better at predicting which treatment would work best compared to a model which used only tissue pathology or clinical factors.

The study strongly supports the case for performing gene profiling of biopsies from arthritic joints before prescribing expensive so-called biologic targeted therapies. This could save considerable time and money and help avoid potential unwanted side-effects, joint damage, and worse outcomes which are common amongst patients. As well as influencing treatment prescription, such testing could also shed light on which people may not respond to any of the current drugs on the market, emphasizing the need for developing alternative medications.

“Incorporating molecular information prior to prescribing arthritis treatments to patients could forever change the way we treat the condition. Patients would benefit from a personalized approach that has a far greater chance of success, rather than the trial-and-error drug prescription that is currently the norm,” said Professor Costantino Pitzalis, Versus Arthritis Professor of Rheumatology at Queen Mary University of London. “These results are incredibly exciting in demonstrating the potential at our fingertips, however, the field is still in its infancy and additional confirmatory studies will be required to fully realize the promise of precision medicine in RA.”

Related Links:
Queen Mary University of London 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Monkeypox Virus Real Time PCR Kit
Monkeypox Virus Real Time PCR Kit
Benchtop Auto Chemistry Analyzer
3-Part Diff Hematology Analyzer
HEMIX 3-60

Print article



view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.